Inotek Pharmaceuticals Secures $18,000,000 Series D Financing Round

  • Feed Type
  • Date
    6/11/2010
  • Company Name
    Inotek Pharmaceuticals
  • Mailing Address
    33 Hayden Avenue 2nd Floor Lexington, MA 02421
  • Company Description
    Inotek Pharmaceuticals Corporation is a private, high-growth, development-stage pharmaceutical company founded in 1996. The Company has leveraged its small molecule chemistry expertise to discover and develop a deep pipeline of therapeutics targeting cell death, DNA repair and inflammatory pathways. Inotek’s lead program is focused on blocking the nuclear DNA repair enzyme, poly (ADP-ribose) polymerase (or PARP), that has broad application in a variety of unmet medical needs.
  • Website
    http://www.inotekcorp.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $18,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from the financing will be used to advance Inotek’s novel eye-drop INO-8875 through multiple-dose Phase 2 clinical trials in glaucoma.
  • M&A Terms
  • Venture Investor
    Devon Park Bioventures
  • Venture Investor
    Care Capital
  • Venture Investor
    Rho Ventures
  • Venture Investor
    MedImmune Ventures
  • Venture Investor
    Bio*One Capital

By posting a comment, you agree to our terms and conditions.